AstraZeneca and Daiichi Sankyo at #ASCO25 (Photo: Max Gelman for Endpoints News)
June 23, 2025 04:03 PM EDT
Pharma
FDA+

As­traZeneca, Dai­ichi Sankyo gain lung can­cer in­di­ca­tion for En­her­tu suc­ces­sor

Max Gelman

Senior Editor

The FDA on Mon­day ap­proved As­traZeneca and Dai­ichi Sankyo’s TROP2-tar­get­ing drug Da­troway in a new lung can­cer in­di­ca­tion, broad­en­ing the amount of pa­tients for what …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Am­gen plans more grad­ual Mar­i­Tide dos­ing in Phase 3 

Act­ing CDER chief is leav­ing af­ter al­most nine years at FDA

Lil­ly’s bima­grum­ab boosts weight and fat loss when added to Novo's We­govy

Up­dat­ed: A puz­zling up­date from No­vo Nordisk and new da­ta from Roche at #ADA25

The pol­i­tics of vac­ci­na­tion take cen­ter stage as RFK Jr.’s re­built CDC pan­el is set to meet

sponsored

Dig­i­tal Twins in GMP Man­u­fac­tur­ing: Shap­ing the Fu­ture of CPV with Aizon

A service from the Financial Times